Peter Casasanto
Corporate Officer/Principal bei SOPHIA GENETICS SA
Profil
Peter Casasanto is currently the Chief BioPharma Officer at SOPHiA GENETICS SA since 2022.
Previously, he worked as the Vice President-New Commercialization Initiatives at CellCarta Biosciences, Inc. Mr. Casasanto has a graduate degree from Thomas Jefferson University, an undergraduate degree from the University of Maryland, and an MBA from Lebow College of Business.
Aktive Positionen von Peter Casasanto
| Unternehmen | Position | Beginn |
|---|---|---|
| SOPHIA GENETICS SA | Corporate Officer/Principal | 10.01.2022 |
Ehemalige bekannte Positionen von Peter Casasanto
| Unternehmen | Position | Ende |
|---|---|---|
CellCarta Biosciences, Inc.
 CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada. | Corporate Officer/Principal | - |
Ausbildung von Peter Casasanto
| Lebow College of Business | Masters Business Admin |
| Thomas Jefferson University | Graduate Degree |
| University of Maryland | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SOPHIA GENETICS SA | Technology Services |
| Private Unternehmen | 1 |
|---|---|
CellCarta Biosciences, Inc.
CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada. | Commercial Services |
